Read This Before Selling Cidara Therapeutics, Inc. (NASDAQ:CDTX) Shares

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we’d be remiss not to mention that insider sales have been known to precede tough periods for a business. So before you buy or sell Cidara Therapeutics, Inc. (NASDAQ:CDTX), you may well want to know whether insiders have been buying or selling.

What Is Insider Selling?

It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, rules govern insider transactions, and certain disclosures are required.

We would never suggest that investors should base their decisions solely on what the directors of a company have been doing. But equally, we would consider it foolish to ignore insider transactions altogether. For example, a Harvard University study found that ‘insider purchases earn abnormal returns of more than 6% per year.’

View our latest analysis for Cidara Therapeutics

Cidara Therapeutics Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when President Jeffrey Stein bought US$1.0m worth of shares at a price of US$4.70 per share. That means that an insider was happy to buy shares at above the current price. It’s very possible they regret the purchase, but it’s more likely they are bullish about the company. It’s not at all bad to see insiders buy shares at or above current prices. Jeffrey Stein was the only individual insider to buy over the year.

You can see the insider transactions (by individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

NasdaqGM:CDTX Recent Insider Trading, March 5th 2019
NasdaqGM:CDTX Recent Insider Trading, March 5th 2019

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Insider Ownership

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data suggests Cidara Therapeutics insiders own 2.1% of the company, worth about US$1.7m. I generally like to see higher levels of ownership.

So What Do The Cidara Therapeutics Insider Transactions Indicate?

The fact that there have been no Cidara Therapeutics insider transactions recently certainly doesn’t bother us. On a brighter note, the transactions over the last year are encouraging. While we have no worries about the insider transactions, we’d be more comfortable if they owned more Cidara Therapeutics stock. Of course, the future is what matters most. So if you are interested in Cidara Therapeutics, you should check out this free report on analyst forecasts for the company.

Of course Cidara Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.